EVAX Evaxion Biotech AS

Evaxion to present at World Vaccine Congress

Evaxion to present at World Vaccine Congress

  • Congress will take place April 21-24, 2025, in Washington, D.C.

COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will give two presentations and man a booth at the World Vaccine Congress taking place April 21-24, 2025, in Washington, D.C.

Birgitte Rønø, Chief Scientific Officer at Evaxion, will talk about the application of Evaxion’s AI-Immunology™ platform for antigen target discovery for cancer vaccines. Pär Comstedt, Vice President, Infectious Disease Vaccine Development at Evaxion, will present the use of AI-Immunology™ for target discovery for infectious disease vaccines. See details on the presentations below.

The World Vaccine Congress is just one of several scientific, partnering and investor conferences where Evaxion will profile itself and discuss with potential partners and collaborators in the second quarter of 2025.

Throughout the conference, Evaxion invites interested parties to its booth #351 for discussions on effective and accurate target discovery with AI-Immunology™ as well as our pipeline of vaccine candidates for cancers and infectious diseases.

Presentation details:

Title:AI-powered antigen target discovery for cancer vaccines
Category:Cancer immunotherapy
Location:Room 206
Date/Time:April 23, 2025, at 11.40 ET/17.40 CET   
Presenter:Birgitte Rønø, Chief Scientific Officer at Evaxion



Title:AI-powered target discovery for infectious disease vaccines
Category:Emerging and re-emerging diseases
Location:Room 202b
Date/Time:April 23, 2025, at 15.10 ET/21.10 CET   
Presenter:Pär Comstedt, VP, Infectious Disease Vaccine Development at Evaxion



Contact information 

Evaxion Biotech A/S

Mads Kronborg

Vice President, Investor Relations & Communication

 

About EVAXION

Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please .

Forward-looking statement 

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at . We do not assume any obligation to update any forward-looking statements except as required by law. 



EN
10/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Evaxion Biotech AS

 PRESS RELEASE

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune resp...

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting 80% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine candidatesThe data underscores the precision of Evaxion’s AI-Immunology™ platform in selecting therapeutically relevant vaccine targetsNew findings show EVX-01 inducing a robust and durable immune response, further enhanced by booster immunizationsThe ongoing phase 2 trial with EVX-01 remains ...

 PRESS RELEASE

Evaxion to present at World Vaccine Congress

Evaxion to present at World Vaccine Congress Congress will take place April 21-24, 2025, in Washington, D.C.COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will give two presentations and man a booth at the World Vaccine Congress taking place April 21-24, 2025, in Washington, D.C.Birgitte Rønø, Chief Scientific Officer at Evaxion, will talk about the application of Evaxion’s AI-Immunology™ platform for antigen target discovery for cancer vaccines. Pär Comstedt, ...

 PRESS RELEASE

Evaxion announces business update and full year 2024 financial results

Evaxion announces business update and full year 2024 financial results COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces full year 2024 financial results.Business highlights2024 and the first months of 2025 saw Evaxion make substantial progress in both business development, research and development and financing. Key highlights are listed below.Our transformational partnership with MSD (Merck Sharp & Dohme LLC, a subsidiary of...

 PRESS RELEASE

Evaxion to announce business update and full year 2024 financial resul...

Evaxion to announce business update and full year 2024 financial results on April 1, 2025 COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before opening of the Nasdaq CM.Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, ...

 PRESS RELEASE

Evaxion to present new phase 2 data for AI-designed personalized cance...

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting These data will further add to the already strong clinical data package for EVX-01The trial remains on track for two-year clinical efficacy data readout in the second half of 2025COPENHAGEN, Denmark, March 25, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch